Factors Impacting Stent Thrombosis in Patients With Percutaneous Coronary Intervention and Coronary Stenting: A

Nso Nso1, Mahmoud Nassar1, Milana Zirkiyeva1

  • 1Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals Queens, New York City, USA.

Cureus
|May 13, 2022
PubMed

Insights

This systematic review found that many baseline characteristics do not predict stent thrombosis (ST) after percutaneous coronary intervention (PCI). Further research is needed to understand complex factors contributing to ST in PCI patients.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Statistics

Background:

  • Stent thrombosis (ST) is a serious complication following percutaneous coronary intervention (PCI).
  • Predicting ST risk based on patient baseline characteristics is crucial for improving outcomes.
  • Existing literature suggests various factors may influence ST, necessitating a comprehensive evaluation.

Purpose of the Study:

  • To systematically review and meta-analyze the diagnostic significance of 18 baseline characteristics in predicting ST risk among adult PCI patients.
  • To statistically evaluate the association between these parameters and ST occurrence.
  • To identify reliable predictors of ST in the context of PCI.

Main Methods:

  • Systematic review and meta-analysis of 18 baseline characteristics in over 15,500 PCI patients.
  • Inclusion of studies from PubMed, JSTOR, Cochrane Library, Google Scholar, and Embase (2005-2021).
  • Statistical evaluation using odds ratios (OR) and confidence intervals (CI) to assess ST attribution.

Main Results:

  • Abnormal left ventricular ejection fraction (LVEF) was associated with increased ST risk (OR: 9.68).
  • Antiplatelet therapy, including aspirin, was associated with a significantly reduced risk of ST.
  • No significant correlation found between ST and acute coronary syndrome (ACS), diabetes mellitus, drug-eluting stents, cardiac biomarker elevation, myocardial infarction, hypertension, BMI, or multivessel coronary artery disease.
  • A prior history of PCI showed a statistically significant association with ST in some studies (p=0.03).

Conclusions:

  • Many commonly assessed baseline characteristics have limited predictive value for stent thrombosis in PCI patients.
  • Antiplatelet therapy appears protective against ST.
  • Further research is required to explore complex interactions of procedural, medicinal, genetic, and patient-related factors in ST development.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
42
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
42
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
39
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
92
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
35
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
50